Analyst: Genmab share price may double
![Photo: Lars Møller / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12896799.ece/ALTERNATES/schema-16_9/doc7fc2rryp1eu101dlg75.jpg)
Genmab has struggled so far in 2021, but certain signs indicate the share may be regaining its momentum, according to an analysis from the Danish bank Jyske Bank.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA grants new Genmab drug priority review status
For subscribers